港股異動 | 中國飛鶴漲超6%,高盛予其目標價21.5港元
uSMART盈立智投11月30日消息,中國飛鶴今日放量上漲,截至10:20分,中國飛鶴漲6.47%,報19.1港元。
高盛發研報指,中國飛鶴於11月27日主辦了2020年年度經銷商大會,公司對其表現非常滿意。高盛稱,該公司對定價和渠道庫存管理的嚴格強調已經生效,並可爲2021年奠定堅實的基礎。
研報續指,在2021年,公司將更多地關注營銷效果、客戶滿意度和新產品的推出,從而有助於其2023年在中國牛奶配方市場實現30%市場份額的目標。從長遠來看,該公司預計銷售額將可持續增加。
高盛予中國飛鶴買入評級 ,目標價21.5港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.